TOTH A ERNEST JR 4
4 · Aquestive Therapeutics, Inc. · Filed Mar 11, 2026
Research Summary
AI-generated summary of this filing
Aquestive (AQST) CFO Ernest Toth Sells 58,254 Shares
What Happened
Ernest Toth, Chief Financial Officer of Aquestive Therapeutics (AQST), reported a sale and new awards. On 2026-03-10 he sold 58,254 shares in an open-market transaction for total proceeds of about $243,094 (weighted-average price $4.17). On 2026-03-09 he was granted 95,000 restricted shares and 70,000 derivative awards (total 165,000) at $0.00 consideration; these awards carry multi-year vesting schedules.
Key Details
- Transaction dates: awards on 2026-03-09; sale on 2026-03-10. Form 4 filed 2026-03-11 (timely filing).
- Sale details: 58,254 shares disposed; weighted-average sale price $4.17; execution prices ranged $4.17–$4.32 (multiple trades); proceeds ≈ $243,094. (Footnote F3.)
- Grants: 95,000 restricted stock units/awards (F1) and 70,000 derivative awards (F4) granted at $0.00; both vest in three annual installments (25% / 25% / 50%).
- Tax-withholding: the sale represents shares sold to cover tax withholding associated with vesting ("sell to cover"), not a discretionary stock-sale decision by the CFO (Footnote F2).
- Shares owned after transaction: not specified in the provided filing excerpt.
- Filing timeliness: appears timely (filed within the Form 4 reporting window).
Context
"Sell to cover" transactions are routine when restricted awards vest and taxes are due; such mandated sales do not necessarily indicate a change in the insider's view of the company. The grants are time‑based and will vest over three years per the footnotes, so their value depends on future share price and vesting.
Insider Transaction Report
- Award
Common Stock
[F1]2026-03-09+95,000→ 434,366 total - Sale
Common Stock
[F2][F3]2026-03-10$4.17/sh−58,254$243,094→ 376,112 total - Award
Non-Qualified Stock Option (right to buy)
[F4]2026-03-09+70,000→ 70,000 totalExercise: $4.29Exp: 2036-03-09→ Common Stock (70,000 underlying)
Footnotes (4)
- [F1]The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.
- [F2]Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
- [F3]This transaction was executed in multiple trades at prices ranging from $4.17 to $4.32. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F4]The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.